Selexis SA

31/05/2023

KBI Biopharma and Selexis consolidating as one organization under the KBI Biopharma name to accelerate innovation and growth for global biopharma customers

17/05/2023

Catch the Webinar Replay: Streamlined Development for Efficient Production of Bispecific Molecules Using an Integrated Platform Process
Learn about our breakthrough platform approach that encompasses the efficient production of bispecific molecules in an integrated, streamlined way, from CLD (cell line development) to cGMP manufacturing. The leverageable integrated workflow from Selexis and KBI Biopharma generates high quality clinical bulk drug substances under accelerated timelines.

Catch The On-Demand Replay Of Our Recent Bispecifics Webinar.

11/05/2023

Question: Does the SUREtechnology Platform use serum-free or chemically defined media and feed from commercial suppliers in large quantities?
Answer: The Selexis CHO-M Cell Line™ (CHO K1 derived) has been optimized for chemically defined (CD), animal-component-free, off-the-shelf media, as well as CD feeds that are commercially available from multiple suppliers. This offers flexibility to our clients and a significant cost-reduction during manufacturing step. It is serum-free, animal component free and chemically defined, ensuring your peace of mind when filling your IND.
More Q&A:

Technology FAQs - Selexis enables biopharmaceutical companies to produce virtually any recombinant therapeutic protein

27/04/2023

Question: Does Selexis have CHO host cell lines that have been adapted or modified to address secretion issues or to perform directed post-translational modifications available?
Answer: Yes, the SURE CHO-Mplus Libraries™ were designed to address such complex issues. These libraries, based on the SURE CHO-M® transcriptome and genome analysis, can help generate products with various post-translational characteristics and attributes, including glycan modifications. Furthermore, the SURE CHO-Mplus Libraries™ enable complex proteins (e.g., multimeric proteins and bispecific mAbs) and difficult-to-express proteins (e.g., fusion proteins) to be folded and secreted in the SURE CHO-M Cell Line™ (Selexis’ CHO K1 derivative cell line).
More Q&A:

Technology FAQs - Selexis enables biopharmaceutical companies to produce virtually any recombinant therapeutic protein

26/04/2023

Catch the Webinar Replay: SUREtechnology Platform to Overcome Phenotypic and Genetic Changes in CHO Cells
CHO cell volumetric productivity has significantly increased in the past two decades. However, turning these cells into high-producing factories has created an overall metabolic burden. In response to transgene expression pressure, CHO cells undergo phenotypic and genetic changes for continuous improvement. Selexis’ SUREtechnology Platform™ provides a solution for overcoming the challenges of high productivity tied to metabolic adaptability.

Catch The On-Demand Replay Of Our Recent Bispecifics Webinar.

13/04/2023

Question: Can Selexis conduct genomic characterization to support RCB generation?
Answer: Yes, Selexis has one of the most comprehensive genomic characterization platforms in the industry. Selexis SUREscan™ technology is based on Selexis’ proprietary bioinformatics tools, which were co-developed with the Swiss Institute of Bioinformatics. Selexis can perform such assays in any mammalian cell, including CHO-K1, SP2/0, HEK-293, and PER.C6 cells.
More Q&A:

Technology FAQs - Selexis enables biopharmaceutical companies to produce virtually any recombinant therapeutic protein

11/04/2023

At Selexis, we have been leading the way in mammalian cell line development for decades. But don't just take our word for it - our track record speaks for itself! 100% of Selexis clients are pleased with the scientific support, long-term partnerships, communication and flexibility, and trust and commitment they receive from Selexis in their cell line development projects. Explore more results from our 2022 recent customer satisfaction survey:

05/04/2023

Webinar Replay: Comprehensive Cell Line Characterization and Genotypic Stability
Genome sequencing has become an essential tool for studying cell line diversity. CHO cell line development benefits greatly from multi-modal sequencing advancements, here we discuss how we comprehensively assess (1) the genomic stability of clones, (2) the location and architecture of transgene integration, and (3) the quality and risk associated with clone selection. Watch the webinar:

Catch The On-Demand Replay Of Our Recent Comprehensive Cell Line Characterization and Genotypic Stability Webinar.

30/03/2023

Question: Do Selexis vectors contain an amplification cassette, such as DHFR or the GS system?
Answer: No, the Selexis SUREtechnology Platform™ does not require gene amplification methods such as MTX/DHFR or GS/MSX. This is all thanks to the Selexis SGE®, which are unique epigenetic DNA-based elements that control the dynamic organization of chromatin in all mammalian cells and enable higher and more stable expression of recombinant proteins.
More Q&A:

Technology FAQs - Selexis enables biopharmaceutical companies to produce virtually any recombinant therapeutic protein

23/03/2023

Selexis and KBI Biopharma have a long history of together. Our collaboration has accelerated more than 60 programs in Europe and worldwide. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe and around the world, our co-located facility supports an integrated, end-to-end process of Selexis' cell line development services along with KBI's contract development and manufacturing services for global industry clients. https://www.kbibiopharma.com/end-to-end-mammalian-services

Under one roof, KBI and Selexis provide services from cell line transfection through to cGMP drug manufacturing with Selexis’ specialized high-titer mammalian cell line development technologies and services and KBI’s cGMP bulk drug manufacturing for clinical and commercial requirements.

17/03/2023

Join Selexis and KBI Biopharma at Festival of Biologics in San Diego next week. Be sure to stop by Booth #49 to chat with Chandra Kelley, VP of Business Development. Looking forward to seeing you there!

KBI Biopharma will be at Festival of Biologics, US this March in San Diego. We look forward to seeing you there!

16/03/2023

Join Selexis and KBI Biopharma at BioEurope Spring next week! Stop by Booth #12 to meet with Nigel Stapleton, Director of Business Development, and Elodie Pothin, Manager of Business Development. We look forward to seeing you in Basel next week!

KBI Biopharma will be at BioEurope Spring this March in Basel. We look forward to seeing you there!